Unknown

Dataset Information

0

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.

ABSTRACT:

SUBMITTER: Rampotas A 

PROVIDER: S-EPMC8558790 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.

Rampotas Alexandros A   Sangha Gina G   Collins Graham P GP  

Therapeutic advances in hematology 20211030

Similar Datasets

Unknown Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
| S-EPMC9344863 | biostudies-literature
Unknown Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
| S-EPMC7698117 | biostudies-literature
Unknown New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
| S-EPMC10778309 | biostudies-literature
Unknown Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.
| S-EPMC8708171 | biostudies-literature
Unknown Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.
| S-EPMC6265691 | biostudies-literature
Unknown Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
| S-EPMC4797019 | biostudies-literature
Unknown Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies.
| S-EPMC8075299 | biostudies-literature
Unknown Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
| S-EPMC11192235 | biostudies-literature
Unknown Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US.
| S-EPMC12622355 | biostudies-literature
Unknown Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
| S-EPMC10707233 | biostudies-literature